Products - Arthritis | Topic | NICE

Showing 40 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Tofacitinib for treating active ankylosing spondylitis (TA920)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Bimekizumab for treating axial spondyloarthritis (TA918)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2023
Bimekizumab for treating active psoriatic arthritis (TA916)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Upadacitinib for treating active ankylosing spondylitis (TA829)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 September 2022
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 September 2022
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 November 2021
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 October 2021
Ixekizumab for treating axial spondyloarthritis (TA718)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Anakinra for treating Still’s disease (TA685)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 December 2020
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2019
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 October 2018
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 January 2018
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2017
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 August 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2017
Ustekinumab for treating active psoriatic arthritis (TA340)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2017
Published:
4 June 2015
Apremilast for treating active psoriatic arthritis (TA433)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2017
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2016
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 January 2016
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2011
Golimumab for the treatment of psoriatic arthritis (TA220)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2011
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010